Michael Hirsh, MD
Urology · Eau Claire, WINPI 1346326428
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,163 of the $3,294 with a category attached, or 65.7%. 27 manufacturers reported payments, led by Neotract Inc. at 29.7% of the total. Reporting peaked in 2022 at $1,031 and has fallen 62.3% since, to $389 in 2025.
Across 84 payments — averaging $39.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neotract Inc.$978
- Teleflex LLC$966
- Intuitive Surgical$276
- Sumitomo Pharma America, Inc.$165
- Boston Scientific$84
- Astellas Pharma US Inc$84
- plus $741 from 21 others
What the payments were for
- Travel & lodging$1,10734%
- Food & beverage$2,16366%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neotract Inc. | 12 | $978 |
| Teleflex LLC | 9 | $966 |
| Intuitive Surgical | 2 | $276 |
| Sumitomo Pharma America, Inc. | 10 | $165 |
| Boston Scientific | 3 | $84 |
| Astellas Pharma US Inc | 5 | $84 |
| AbbVie(2 entities) | 5 | $79 |
| AstraZeneca | 4 | $72 |
| Johnson & Johnson | 4 | $62 |
| Progenics Pharmaceuticals, Inc. | 3 | $48 |
| Bayer | 2 | $46 |
| Tolmar, Inc. | 2 | $44 |
| Accord Healthcare, Inc. | 2 | $42 |
| Myovant Sciences Inc. | 2 | $39 |
| Pfizer | 2 | $37 |
| Laborie Medical Technologies Corp. | 2 | $36 |
| Ferring Pharmaceuticals Inc. | 2 | $36 |
| Axonics, Inc. | 2 | $34 |
| Antares Pharma, Inc. | 2 | $30 |
| Blue Earth Diagnostics | 2 | $29 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $25 |
| Merck | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| Urogen Pharma, Inc. | 1 | $14 |
| Coloplast | 1 | $13 |
| KARL Storz Endoscopy-america | 1 | $12 |
| Photocure Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$934
- UroLift System$585
- Da Vinci Surgical System$276
How this compares
$3,294 in reported general payments places this provider in the 75th percentile of 215 urology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 11 | $166,125 |
| MyrbetriqMirabegron | 51 | $28,219 |
| GemtesaVibegron | 21 | $19,376 |
| Solifenacin Succinate | 171 | $8,483 |
| Oxybutynin Chloride ErOxybutynin Chloride | 238 | $7,293 |
| Tamsulosin Hcl | 313 | $4,412 |
| NitrofurantoinNitrofurantoin Macrocrystal | 90 | $2,951 |
| Potassium Citrate ErPotassium Citrate | 20 | $2,471 |
| Desmopressin Acetate | 41 | $2,397 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 19 | $2,386 |
| Finasteride | 177 | $2,340 |
| Testosterone | 16 | $2,234 |
| Tolterodine Tartrate ErTolterodine Tartrate | 26 | $1,731 |
| Abiraterone Acetate | 11 | $1,589 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 75 | $528 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $62 | $166,12511 claims |
| Astellas Pharma US IncMyrbetriq | $84 | $28,21951 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $165 | $19,37621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 215 urology providers in Wisconsin.
Other urology in Eau Claire
- Josiah NelsonEau Claire$13K
- James IwakiriEau Claire$5K
- Christopher TornehlEau Claire$3K
- Dan GralnekMadison$142K
- Amy GuiseMilwaukee$106K
- Christopher ManakasMadison$87K
- Bahareh Alavi-DunnGreen Bay$62K
- Javier SantiagoMadison$57K
- Kevin FlynnNeenah$56K
- Margaret KnoedlerMadison$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.